Medicus Pharma Highlights Positive Teverelix Phase 1 Data and Near-Term SkinJect Milestones

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialMedicus Pharma Ltd ( (MDCX) ) has shared an announcement. Medicus Pharma reported Phase 1 data showing that its long-acting GnRH antagonist Teverelix achieved rapid, reversible suppression of reproductive hormones in healthy premenopausal women, while maintaining stable bone turnover markers and a favorable safety profile. The data, accepted for presentation at the 2026 American Association of Clinical Endocrinology meeting, support Teverelix’s potential expansion into women’s health, particularly endometriosis, and complement its ongoing development in prostate cancer and acute urinary retention relapse prevention; in parallel, the company’s SkinJect™ Phase 2 trial in basal cell carcinoma has completed enrollment, with topline data expected in early 2026 and an FDA End-of-Phase 2 meeting planned for the first half of the year, underscoring Medicus’s strategy of de-risking assets through Phase 2 and pursuing partnerships for late-stage development. The most recent analyst rating on (MDCX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page. Spark’s Take on MDCX Stock According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral. The score is driven primarily by weak financial performance (no revenue, widening losses, rising cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Valuation is constrained by negative earnings and no dividend support, partially offset by a modestly positive liquidity-related financing event. To see Spark’s full report on MDCX stock, click here. More about Medicus Pharma Ltd Medicus Pharma Ltd. is a precision-guided biotech and life sciences company focused on advancing novel, potentially disruptive therapeutic assets through early- to mid-stage clinical development. Its portfolio includes Teverelix, a long-acting gonadotropin-releasing hormone (GnRH) antagonist being developed for prostate cancer, acute urinary retention relapse prevention and women’s health indications, as well as SkinJect™, a dissolvable microneedle array delivering doxorubicin for non-invasive treatment of basal cell carcinoma. Average Trading Volume: 322,889 Technical Sentiment Signal: Sell Current Market Cap: $39.18M See more data about MDCX stock on TipRanks’ Stock Analysis page.